In January 2026, Vir Biotechnology reported new positive data from its ongoing SOLSTICE Phase 2 trial in chronic hepatitis delta, where combination therapy with investigational agents tobevibart and ...
The fast-spreading delta variant of the coronavirus has been gaining traction worldwide since it was first detected in India. It’s a version of the coronavirus that has been found in more than 80 ...
SAN FRANCISCO (KGO) -- The Centers for Disease Control and Prevention (CDC) released new data Friday indicating the Delta variant is twice as infectious as previously thought, and a recent analysis ...
Mirum Pharmaceuticals has entered a definitive agreement to acquire Bluejay Therapeutics — a deal that, if finalized, would add brelovitug, a phase 3-stage monoclonal antibody for chronic hepatitis ...
Mirum Pharmaceuticals acquires Bluejay Therapeutics, focusing on brelovitug for chronic hepatitis delta virus (HDV), a severe ...
The Nation (PK) on MSN
Health ministry, DRAP to combat hepatitis delta virus through global collaboration
The Ministry of National Health Services, Regulations and Coordination, in collaboration with the Drug Regulatory Authority ...
Findings showed 100% of participants taking the tobevibart and elebsiran combination achieved an undetectable HDV RNA at week 24 that was sustained through week 60. The Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results